0000950170-24-095094.txt : 20240812
0000950170-24-095094.hdr.sgml : 20240812
20240812090003
ACCESSION NUMBER: 0000950170-24-095094
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240806
FILED AS OF DATE: 20240812
DATE AS OF CHANGE: 20240812
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HUNT RONALD
CENTRAL INDEX KEY: 0001247851
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38503
FILM NUMBER: 241195096
MAIL ADDRESS:
STREET 1: C/O CREDIT SUISSE 1ST BOSTON PRV EQY
STREET 2: 11 MADISON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Iterum Therapeutics plc
CENTRAL INDEX KEY: 0001659323
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: FITZWILLIAM COURT, 1ST FLOOR
STREET 2: LEESON CLOSE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 YW24
BUSINESS PHONE: (872) 225-6077
MAIL ADDRESS:
STREET 1: FITZWILLIAM COURT, 1ST FLOOR
STREET 2: LEESON CLOSE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 YW24
FORMER COMPANY:
FORMER CONFORMED NAME: Iterum Therapeutics Ltd
DATE OF NAME CHANGE: 20151124
4
1
ownership.xml
4
X0508
4
2024-08-06
0001659323
Iterum Therapeutics plc
ITRM
0001247851
HUNT RONALD
C/O ITERUM THERAPEUTICS PLC
FITZWILLIAM COURT, FL. 1, LEESON CLOSE
DUBLIN 2
L2
IRELAND
true
false
false
false
false
Ordinary Shares
2024-08-06
4
M
false
182453
A
253898
I
By New Leaf Ventures III, L.P.
Ordinary Shares
2024-08-06
4
M
false
65481
A
91122
I
By New Leaf Biopharma Opportunities II, L.P.
Subscription Rights (right to buy)
0.61
2024-08-06
4
M
false
364906
0
D
2024-07-22
2024-08-06
Units
0
I
By New Leaf Ventures III, L.P.
Warrants (right to buy)
1.21
2024-08-06
4
M
false
182453
A
2024-08-09
2025-08-09
Ordinary Shares
91226
182453
I
By New Leaf Ventures III, L.P.
Warrants (right to buy)
1.21
2024-08-06
4
M
false
182453
A
2024-08-09
2029-08-09
Ordinary Shares
182453
182453
I
By New Leaf Ventures III, L.P.
Subscription Rights (right to buy)
0.61
2024-08-06
4
M
false
130962
0
D
2024-07-22
2024-08-06
Units
0
I
By New Leaf Biopharma Opportunities II, L.P.
Warrants (right to buy)
1.21
2024-08-06
4
M
false
65481
A
2024-08-09
2025-08-09
Ordinary Shares
32740
65481
I
By New Leaf Biopharma Opportunities II, L.P.
Warrants (right to buy)
1.21
2024-08-06
4
M
false
65481
A
2024-08-09
2029-08-09
Ordinary Shares
65481
65481
I
By New Leaf Biopharma Opportunities II, L.P.
The reported securities were purchased in the Issuer's rights offering (the "Offering") which closed on August 9, 2024. As part of the Offering, New Leaf Ventures III, L.P. ("NLV-III") purchased 182,453 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance ("1-year warrants"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance ("5-year warrants").
These shares are held directly by NLV-III. New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NLVM-III LLC and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person disclaims Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of his pecuniary interest therein, if any.
The reported securities were purchased in the Issuer's rights offering (the "Offering") which closed on August 9, 2024. As part of the Offering, New Leaf Biopharma Opportunities II, L.P. ("NBPO-II") purchased 65,481 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance ("1-year warrants"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance ("5-year warrants").
These shares are held directly by NBPO-II. New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NBPO-IIM and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person disclaims Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of his pecuniary interest therein, if any.
NLV-III validly exercised 364,906 subscription rights to acquire 182,453 units composed of (i) 182,453 ordinary shares, (ii) 182,453 1-year warrants and (iii) 182,453 5-year warrants.
NBPO-II validly exercised 130,962 subscription rights to acquire 65,481 units composed of (i) 65,481 ordinary shares, (ii) 65,481 1-year warrants and (iii) 65,481 5-year warrants.
/s/ Ronald M. Hunt
2024-08-12